Absci Corporation (ABSI)
(Delayed Data from NSDQ)
$3.91 USD
-0.13 (-3.22%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABSI 3.91 -0.13(-3.22%)
Will ABSI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABSI
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
ABSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
Other News for ABSI
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Absci management to meet with Truist
Absci management to meet with Truist
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024